21
Participants
Start Date
May 31, 2003
Primary Completion Date
June 30, 2006
Study Completion Date
August 31, 2006
Peginterferon Alfa-2a and Ribavirin
"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
Ribavirin
Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
Weill Medical College of Cornell University, New York
Children's Hospital Philadelphia, Philadelphia
Children's Hospital and Research Center at Oakland, Oakland
Toronto General Hospital, Universty Health Network, Toronto
University College London, London
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Carelon Research
OTHER